| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| According to the responses of PIR , the agents used were categorized into three patterns : FRO increased PIR , both PGs lowered PIR , and , CAP and Ang 2 A had no effect on PIR release . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| The response rates for CAP , PP and CAV were 18 . 3 % ( 11 PR ) , 20 . 7 % ( 6 PR ) and 60 % ( 10 CR + 11 PR ) , respectively . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| In the CAP treated group , a clinical response was obtained in 1 of CR and in 2 of PR out of the 9 patients with evaluable lesions ( 33 . 3 % ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| On the other hand , in the CAP treated group , a 50 . 0 % CR plus PR rate and a 88 . 9 % downstaging were noted . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| The overall response rates ( complete response [ CR ] plus partial response [ PR ] ) on the chemotherapy arms were CAP , 15 . 3 % , and VP , 25 . 3 % ( P = . 06 ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| On the basis of the final results the authors underline some data which , although merely indicative ( because of the small number of patients ) appear to be worth considering since they are in accordance with the latest reports : a ) similar response rate ( CR + PR = 47 % ) to first line treatment in the two groups ; b ) the CAP treatment may achieve a longer median duration of CRs than the P treatment ( 20 versus 11 months ) ; c ) overall survival seems similar in the two groups of patients ( 19 versus 18 months ) , whereas the survival of CRs seems longer in the CAP treated patients ( greater than 32 versus 25 months ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| CCRT improved the response rate [ complete response ( CR ) plus partial responses ( PR ) ] from 25 % after two courses of CAP alone to 65 % after CCRT . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| An objective response ( CR + PR ) to CAP combination chemotherapy was achieved in 72 % of patients ( 43 / 61 ) , with a high rate ( 36 % ) of complete remissions . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| Cytosol receptors for estrogens ( ER ) and progestins ( PR ) were assayed in human prostatic carcinoma ( CaP ) and benign prostatic hyperplasia ( BPH ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| An objective response ( CR + PR ) to CAP combination chemotherapy was achieved in 75 % of patients ( 27 of 36 ) , with a high rate ( 42 % ) of complete remissions . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| The rates of partial remission ( PR ) and overall response ( CR + PR ) were , respectively , 75 % and 94 % for the FDB treated patients , 64 % and 75 % for the CHOP treated patients , and 65 % and 72 % for the CAP treated patients . ^^^ However , in patients with stage C CLL ( n = 77 ) at entry to the study , the remission status at 6 months showed slightly greater improvement in the CAP treated group ( n = 25 ) , in which 84 % of patients achieved remission ( CR + PR ) compared with 64 % of patients in the FDB treated group ( n = 27 ) and 63 % of patients in the CHOP treated group ( n = 27 ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| The overall response rate ( CR + PR ) was 62 . 5 % in CAP 1 , and 50 % in CAP 2 ( on statistical difference : NS ) . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| RESULTS : In the first three months , 6 ( 6 / 15 ) complete remissions ( CR ) and 2 ( 2 / 15 ) partial remissions ( PR ) were observed in the CSA group while only 2 ( 2 / 15 ) PRs were observed in the CAP group . ^^^ No additional CR or PR was observed in the CAP group during late follow up . ^^^ In the CAP group , 3 spontaneous CRs occurred beyond 1 . 5 year ' s follow up , with 3 CR and 2 PR at the last visit . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| The immunoprofile was similar to normal cap cells with one exception ; whereas normal cells were uniformly negative for PR , nuclear positivity was seen in 64 % of hyperplasias , a frequency similar to that of benign meningiomas . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| RESULTS : In the CAP group , complete response ( CR ) was observed in six patients and partial response ( PR ) in three , for an RR of 64 . 3 % . ^^^ |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: Q9BX66 and P06401 |
Pubmed |
SVM Score :0.0 |
| NA |
|